Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.

British journal of pharmacology - 1 May 2006

Fredj Sandra, Sampson Kevin J, Liu Huajun, Kass Robert S

Abstract excerpt

1 We studied the effects of ranolazine, an antianginal agent with promise as an antiarrhythmic drug, on wild-type (WT) and long QT syndrome variant 3 (LQT-3) mutant Na(+) channels expressed in human embryonic kidney (HEK) 293 cells and knock-in mouse cardiomyocytes and used site-directed mutagenesis to probe the site of action of the drug. 2 We find preferential ranolazine block of sustained vs peak Na(+) channel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sodium
Share to Action Potentials
Share to Anesthetics, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Arrhythmia Agents

Share to Long QT Syndrome

Share to Models, Cardiovascular

Share to NAV1.5 Voltage-Gated Sodium Channel

Share to Sodium Channel Blockers

Source

Open in PubMed Open full text

Identifiers

PMID: 16520744
DOI: 10.1038/sj.bjp.0706709
PMCID: PMC1617037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.PMID 16520744Read ↗

Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.Semantic proximity Read ↗

Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Semantic proximity Read ↗

Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation.Semantic proximity Read ↗

State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.Semantic proximity Read ↗

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.Semantic proximity Read ↗

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?Semantic proximity Read ↗

Lidocaine block of LQT-3 mutant human Na+ channels.Semantic proximity Read ↗

Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers.Semantic proximity Read ↗

Mechanism of lidocaine block of late current in long Q-T mutant Na+ channels.Semantic proximity Read ↗

The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner.Semantic proximity Read ↗

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine.Semantic proximity Read ↗

The Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin Inhibits Long QT 3 Late Sodium Currents in a Mutation Specific MannerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.